

of the amino acids of position 70 to position 85 or 84, respectively, on condition that it keeps intact (in particular unsubstituted) the portion $\text{RAPR}_{76}\text{S}_{77}\text{P}$ (SEQ ID NO: 5).

It is therefore a peptide comprising a sequence derived from the sequence $\text{X-Y}_{70}\text{TLRAPR}_{76}\text{S}_{77}\text{PKMVQGS}_{85}\text{-Z}$ (SEQ ID NO: 4) (II) or from the sequence $\text{X-Y}_{70}\text{TLRAPR}_{76}\text{S}_{77}\text{PKMVQGS}_{84}\text{-Z}$ (SEQ ID NO: 108) (III) by substitution of one or more among the amino acids Y_{70} , T_{71} , L_{72} , K_{79} , M_{80} , V_{81} , Q_{82} , G_{83} , S_{84} and G_{85} , with it being possible for X to be absent or to represent either an NH_2 function, or 1 to 3 amino acids not belonging to the sequence of proBNP(1-108), and it being possible for Z to be absent or to represent either an OH function, or 1 to 3 amino acids not belonging to the sequence of proBNP(1-108).

²¹
~~Rewrite page 12, line 26, through page 14, line 1.~~

CR
3/20/09

A subject of the invention is also a method for obtaining anti-proBNP(1-108) antibodies that specifically recognize the sequence $\text{Y}_{70}\text{TLRAPR}_{76}\text{S}_{77}\text{PKMVQGS}_{85}$ (SEQ ID NO: 4), $\text{Y}_{70}\text{TLRAPR}_{76}\text{S}_{77}\text{PKMVQGS}_{84}$ (SEQ ID NO: 108) and/or the sequence $\text{RAPR}_{76}\text{S}_{77}\text{P}$ of proBNP(1-108) with the substantial exclusion of BNP(1-76) and of BNP(77-108), and that have the ability to specifically recognize circulating proBNP(1-108) in human serum or plasma samples, characterized in that an animal is immunized with a peptide of formula:

